Company has discontinued Decoy20 clinical development and is evaluating strategic alternatives for its operations
Indaptus says future activities will depend on scientific validation, market opportunities, and available resources
Drivers of the decline in expenses
Lower clinical costs - Decrease in research and development expenses mainly due to reduced clinical costs for Decoy20 and lower payroll after headcount and salary cuts
Reduced administrative expenses - General and administrative costs declined due to lower payroll and changes in public-company costs during management transition
Quarterly results and cost reductions
U.S. immunotherapy biotech's Q2 net loss narrowed, driven by lower clinical and payroll costs
Company discontinued Decoy20 clinical study and has no active clinical development programs
Liquidity position improved after $12 mln private placement completed in June 2026
INDP•
